A hundred and eight patients less than 60 years old with de novo acute myeloid leukemia were treated between 1982 and 1994 by protocols including final intensification with a transplant using autologous bone marrow purged by mafosfamide in first remission in the absence of an HLA-matched sibling donor available for allograft. From 1989, we attempted to improve tumor control by using high-dose anthracyclines in induction, by increasing from one to two the number of consolidation courses pre-transplant and by introducing intermediate doses of cytarabine in the first consolidation course. The CR rate was 77% (33/43) before 1989 and 90% (59/65) after 1989 (P = 0.06). Forty-five out of the 59 patients (76%) who achieved CR after 1989 could undergo bone marrow grafting in CR1 vs 16/33 (48%) before 1989 (P = 0.01). In spite of the higher proportion of patients above 50 years after 1989 (32%) toxicity was mild and an adequate graft was obtained more frequently after one collection. The principal factor relating to improvement in graft feasibility was the post-1989 modification of induction and consolidation regimens. This improvement in graft feasibility was associated with a better disease-free survival (DFS) (48 ± 7% vs 32 ؎ 8%, P = 0.04) and overall survival (OS) (53 ± 6% vs 30 ± 7%, P = 0.007) at 5 years. By multivariate analysis four factors were associated with overall survival (OS): karyotype, white blood cell count at diagnosis, treatment regimen and bone marrow grafting in CR1. This global approach should be prospectively compared with intensive chemotherapy. Keywords: acute myeloid leukemia; intensive chemotherapy; ABMT Allogeneic and autologous bone marrow transplantation are two available therapeutic options for patients with acute myeloid leukemia (AML) in complete remission. Both approaches have been shown to improve disease-free survival when compared with chemotherapy.
Allogeneic and autologous bone marrow transplantation are two available therapeutic options for patients with acute myeloid leukemia (AML) in complete remission. Both approaches have been shown to improve disease-free survival when compared with chemotherapy. [1] [2] [3] Until recently, allogeneic bone marrow transplantation (BMT) has usually been the approach for patients under 50 years of age. The major limitation to BMT is the availability of an HLAidentical sibling donor. Indeed the real number of patients who finally receive BMT is low. 4 Moreover, the full success of BMT is reduced by the high incidence of transplantrelated mortality. 5 Autologous bone marrow transplantation (ABMT) has no donor limitation, but the main impediment is a high relapse rate. 1, 6 In 1982, we implemented a policy to treat every adult patient with acute leukemia under 60 years of age, who was not able to receive BMT in first complete remission (CR1), with intensive therapy and ABMT. To reduce the risk of contamination of the graft by leukemic blast cells every sample was treated ex vivo with mafosfamide. 7 Bone marrow harvesting was always carried out after consolidation therapy and only in the absence of any detectable minimal residual disease, using routine means available at the time of treatment. In an effort to increase the remission rate and maintain the remission status until intensification, we increased doses of anthracyclines and introduced intermediate doses of aracytine, respectively. From 1989, we used a new first-line induction regimen effective in refractory AML, the DON, 8 which we previously developed for resistant disease, followed by two courses of consolidation before marrow collection. The first one combined intermediate-dose cytarabine and amsacrine, the second, cytarabine and etoposide. To evaluate the feasibility of this policy and the results, we retrospectively analyzed all consecutive adult patients with previously untreated acute myelogenous leukaemia who were given chemotherapy at Saint-Antoine Hospital from January 1982 until December 1994, and we evaluated the number of patients who actually underwent bone marrow transplantation in first remission. For each of the two periods (1982-1989 and 1989-1994 ) the reasons why some patients did not reach transplantation, and the factors associated with the feasibility of the graft in CR1 were analyzed. In addition, we evaluated the long-term results and the factors associated with disease-free survival (DFS) and overall survival (OS) for the whole population (intention to treat) and for the patients who underwent grafting in CR1. We found that in the more recent time period we have been able to almost double the number of patients reaching autologous bone marrow transplantation and this has resulted in an improvement in DFS and OS.
Materials and methods

Patients
This retrospective study involved 108 consecutive patients (59 men and 49 women), 15 to 60 years old (median, 39 years), treated for de novo acute myeloid leukemia (AML) in the Department of Hematology at Hopital Saint Antoine, Paris, France between January 1982 and December 1994. Cytogenetics were performed at diagnosis in 82% of patients and found to be abnormal in 56% of cases. Chromosome abnormalities were classified according to proposals set out by Bloomfield. 9 Patient characteristics are given in Table 1 . There was no significant difference in the characteristics of the patients treated before and after 1989 except for the proportion of patients above 50 years which was significantly higher after 1989: 32% vs 14% before 1989 (P = 0.04). The data were analyzed in December 1997 with the last follow-up available for all patients still alive, apart from three patients who were lost to follow-up at 3, 5 and 30 months after diagnosis. The median follow-up was 39 months . Patients diagnosed before 1986 were followed up at least 10 years. The last information was collected during 1997 except for three patients who were last contacted in 1996.
Protocols used during the study period were approved by the Institutional Review Committee.
Treatment
All patients were treated following protocols which included final intensification with hemopoietic stem cell transplantation using the following therapeutic plan: induction, consolidation and graft in CR1 (allograft if an HLAmatched sibling donor was available or autograft otherwise) ( Figure 1 ). All patients were initially assigned for transplantation.
Induction 2 from days 1 to 3). Bone marrow harvest (BMH) was carried out after checking for the absence of residual tumor on cytological, histological and cytogenetic examination. Two thirds of the marrow was treated in vitro with mafosfamide and cryopreserved to be reinfused to the patient; one third was untreated and stored as a back-up. The graft was considered satisfactory if it contained more than 10 4 CFU-GM/kg. If necessary a second harvest was performed under the same conditions. CFU-GM determination was done on agar using placenta-conditioned medium, as described, 7 with evaluation at 10 days. This technique was used over the two study periods, even though parallel evaluation of earlier CFU-GM progenitors on methyl cellulose with cytokines and scoring on days 14-18 has also been applied to the marrow collections since 1990, to allow comparisons.
The autograft was then performed as quickly as possible. Transplant regimens consisted of the combination of cyclophosphamide (120 mg/kg) + TBI (10 Gy) or busulfan (16 mg/kg) + cyclophosphamide (200 mg/kg) in patients under 50 years of age and the BAVC (BCNU, AMSA, VP16, cytarabine) in patients aged over 50 years of age. Injection of the cryopreserved bone marrow was carried out at least 24 h following chemotherapy. Allografts were also carried out as quickly as possible after the same consolidation courses, in patients under 45 years of age. The preallograft conditioning regimens were the same as for ABMT. Prophylaxis for graft-versus-host disease was the combination of cyclosporine and methotrexate.
Endpoints
Complete remission (CR) was defined as a normocellular bone marrow aspirate containing less than 5% blast cells with evidence of normal maturation of all lineages and normal blood counts (Hb у11 g/dl, neutrophils у1.5 × 10 9 /l, platelets у100 × 10 9 /l, absence of circulating leukemic Bone Marrow Transplantation blast cells) over a period of at least 1 month. 10 Remission failures combined toxic death and resistant disease. 11 
Statistical analysis
Fischer's exact test was used to compare qualitative variables and the Wilcoxon's test to compare continuous variables. Variables considered in this analysis included age (below and above 50 years), gender, white blood cell count at diagnosis (below and above 30 × 10 9 /l), cytogenetics (poor risk karyotype vs others), dose of anthracyclines at induction (standard vs higher doses), number and type of consolidation (conventional vs intermediate dose of Ara-C), period of treatment (before and after 1989). Factors influencing graft feasibility were studied by univariate analysis and multivariate analysis using logistic regression; odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the relation with each explanatory variable. Survival and disease-free survival (DFS) were estimated using the Kaplan-Meier method. Comparison between groups was based on the log rank test.
While the survival times of patients who have received a bone marrow transplant in CR1 cannot be compared with those that have not, the Cox proportional hazards model with time-dependent variables was used for performing multivariate analysis of prognostic variables after taking into account the waiting time from complete remission until transplantation.
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Results
Remission rate
Ninety-two out of the 108 patients (85%) achieved CR, 64 after a single course of induction chemotherapy.
CR rate was 77% (33/43) before 1989 and 90% (59/65) after 1989. Achievement of CR after one course occurred in 44% (19/43) during the first period and in 69% (45/65) during the latter period (P = 0.02).
The incidence of primary resistant leukemia dropped significantly between the two periods from 19% (8/43) to 6% (4/65) (P = 0.06).
Six patients (three before 1989, three after 1989) died during induction therapy (5.5%) including two with resistant disease.
Graft feasibility
Sixty-one patients underwent intensive therapy with bone marrow grafting in CR1 (54 autografts and seven allografts) which represents 56% of the total population and 66% of the patients who achieved CR. The reasons why 47 patients could not be grafted in CR1 were as follows: refractory leukaemia (n = 12), early relapse (n = 17), toxicity linked to the treatment (n = 14 with nine deaths, six during induction and three during consolidation), refusal (n = 1) and various others (n = 3). The median interval from CR to graft was 5 months (range, 2-17) for ABMT and 4 months (range, 2-5) for BMT.
As shown in Table 2 , graft feasibility improved during the latter period 1989-1994 in comparison to the former. Forty-five out of the 59 patients (76%) who achieved CR after 1989 underwent bone marrow grafting in CR1 vs 16/33 (48%) before 1989 (P = 0.01), ie 69% of the total population at diagnosis vs 37% previously (P = 0.001). This improvement was associated with a significant reduction in the number of patients with primary resistance or early relapse (P = 0.007). In spite of the increase in median age, with a significant higher proportion of patients over 50 years after 1989, the reinforced treatment was not associated with more toxicity (16% before 1989 vs 11% afterwards). Likewise, in patients who underwent bone marrow harvesting, an adequate graft sample, as defined in our prerequirements, was obtained after one collection more frequently after 1989 than before (88% vs 58%; P = 0.01). Further, the median richness of the marrows collected after 1989 was higher (5.92 vs 3.24 × 10 4 CFU-GM/kg) ( Table 2) .
Among the 92 patients who achieved CR, the principal factor relating to graft feasibility was the nature of the treatment given (induction and/or consolidation), while age, gender, karyotype, leukocytosis, or FAB category did not influence access to transplantation. As both induction and consolidation regimens were modified in the more recent period it was not possible to assess these for their respective influence. Compared to any other treatment combination, patients who received the high dose of anthracycline during induction and the post-1989 consolidation regimen were twice as likely to have bone marrow grafting (odds ratio, 2.7; 95% confidence interval, 1.07-6.80; P = 0.05).
Outcome
For the whole population an improvement in OS and in DFS was observed during the last period. OS calculated from diagnosis for the whole population was 53 ± 6% at 5 years among the patients treated after 1989 vs 30 Ϯ 7% for the patients treated before 1989 (P = 0.007) (Figure 2 ). DFS calculated from CR was 48 ± 7% at 5 years after 1989 vs 32 ± 8% before 1989 (P = 0.04) (Figure 3) . In both periods, the outcome of patients not transplanted was dismal (a median survival of 18 months after 1989 and 9 months before, P = 0.90).
Multivariate analysis identified four factors associated with OS: karyotype, WBC, treatment regimen and bone marrow grafting in CR1 (Table 3) . Patients who received a high dose of anthracycline during induction and the post-1989 consolidation regimen had a significantly better OS than did patients who received any other treatment combination. After adjustment on patient characteristics and treatment regimens, a significant benefit for bone marrow grafting remained (P = 0.06).
As for the DFS, two factors only were associated on multivariate analysis with this improvement: the absence of poor risk karyotype and an induction with high-dose anthracycline.
For the 61 patients who actually underwent bone marrow grafting in CR1 overall survival and DFS at 5 years after transplantation were respectively 61 ± 6% and 55 ± 7%, with a post-graft median follow-up of 41 months (1-161) . A trend towards a better survival and better DFS at 5 years calculated from transplantation was observed among the patients treated after 1989 (OS: 67 ± 7% compared to 43 ± 13%, P = 0.06; DFS 60 ± 8% compared to 43 ± 13%, P = 0.10) (Figures 4 and 5) .
Thirty-three out of these 61 patients (54%) (29 ABMT and four BMT), maintained CR with a CR post-graft median time of 58 months (range, 17-161). Twenty-one patients (34%) relapsed at a median of 6 months, 17 (81%), within the first 15 months post-grafting. Seven patients died as a result of toxicity, two during graft procedure and five at 2, 7, 17, 19 and 81 months, respectively (one sudden death, two chronic GVH disease, one multifocal leukoence- phalitis and for one fulminant sepsis as a complication of previous splenectomy).
Discussion
Since 1982 all patients in our institution under 60 years of age with AML in CR1 have been assigned to receive an intensification with ABMT, in the absence of a related donor. This approach was founded on the assumption that AML may be cured if high-dose therapy including TBI and purged marrow for ABMT are given at the time when minimal residual disease is at its lowest. This strategy has resulted in a disease-free survival of 58% ± 7% at 8 years 13 in patients autografted in CR1. A recent update 14 has further identified the richness of the marrow collected (evaluated before purging) and the residual CFU-GM fraction post purging as the two strongest prognostic factors for outcome. Indeed, the group of patients receiving the highest dose of stem cells prepurging combined with the lowest CFU-GM residual fraction post purging has a dis-ease-free survival of 70% at 10 years. However, these results concern only those patients who reached the last step of the therapeutic strategy, ie autografting.
In this report, we have shown that it also has been possible to significantly increase the number of patients reaching transplantation with an improvement of DFS and OS. Indeed, for the last 65 patients treated after 1989, 76% of those in CR underwent the final procedure vs 48% only before 1989 (P = 0.01), with a DFS and an OS in the last period of respectively 48 ± 7% and 53 ± 6% at 5 years compared with 32 ± 8% and 30 ± 7% before 1989 (log rank P = 0.04 and P = 0.007). Interestingly, we found that more chemotherapy as administered after 1989, did not induce poorer stem cell harvests and indeed increased accessibility to autografting, an important improvement further emphasized by the fact that the patient population was older after 1989 than before.
Three factors were associated with a better outcome: karyotype, treatment regimen (induction and/or consolidation) and final intensification with bone marrow transplantation.
The impact of karyotype and high-dose anthracyclines has been previously emphasized in several studies. [15] [16] [17] [18] Cytogenetics in AML have been shown to be the most important prognostic factor with all therapeutic strategies, either conventional chemotherapy or allogeneic or autologous transplantation. 2, 6, 19 There is a general agreement that t(8;21), t(15;17) and inv(16) are a favourable group with high remission rates and high prolonged DFS. Conversely, patients with abnormalities of chromosome 5, monosomy 7, 3q− and complex changes have a poor prognosis for survival.
1,2,6 Our two patient populations did not differ regarding cytogenetics. No objectively demonstrated improvement has been achieved in this poor risk patient category and we, as others, have not succeeded in our efforts to reduce early relapse post autografting.
The impact of intensive induction therapy on DFS is suggested by several studies: Bishop et al 20 were the first to obtain a significant improvement in DFS by reinforcing induction through the administration of aracytine at high dosage (5 years DFS of 41% vs 23% with standard-dose aracytine). Mitus et al 21 showed in a retrospective study that the addition of aracytine at a dose of 4 g/m 2 /day from day 8 to day 10 to a standard 3 + 7 induction resulted in a post-transplant DFS of 62% at 4 years for the patients able to complete the entire procedure. Castaigne et al 22 also reported a very satisfactory DFS post single chemotherapy (53% at 3 years) using a protocol reinforcing induction by increasing doses of aracytine and anthracycline. The beneficial role of high-dose aracytine given in consolidation has also been clearly demonstrated, in a three arm randomized study 23 over low-or even intermediate-dose aracytine. In our study it was not possible to assess their respective influence on DFS and OS as both induction and consolidation regimens were modified in the more recent period, whereas they contributed to graft feasibility.
The favorable effect of bone marrow transplantation is usually reported with regard to DFS, but not OS. When compared with intensive chemotherapy, allo and autografting had a positive impact on DFS in the EORTC study 1 as in the MRC study 2 but did not improve OS, because patients relapsing in the chemotherapy arm were sometimes 'rescued' by transplantation in CR2. In some other trials, the benefit of ABMT was not obvious over high-dose aracytine used alone. 6, 24 However, in the most recent US intergroup study, analyzing results by cytogenetic categories indicated that both autologous and allogeneic stem cell transplantation were superior to high-dose aracytine in the favorable group, while ABMT gave the worst results in the poor risk category. 25 That the bone marrow transplantation itself contributed to improved outcome is emphasized by the fact than the OS for the non-transplanted group was identically disastrous before and after 1989 (a median survival of 9 and 8 months respectively, before and after 1989; log-rank, P = 0.90). In the two periods the majority of the patients who did not get bone marrow transplantation in CR1 were poor risk patients.
Thus, this significant improvement in the feasibility of ABMT associated with a low rate of transplant-related mortality gives probably the best opportunity to evaluate the real impact of BMT on OS in ideal conditions, whereas in other trials, most of the patients did not receive the intended treatment.
The fact than bone marrow grafting in CR1 (essentially ABMT in our experience) contributes independently to improving DFS and OS emphasizes the necessity of better accessibility to transplantation. In our study, we have shown that it has been possible to increase the dose of chemotherapy during induction and consolidation while maintaining the chance for patients not eligible for a genotypic allograft to undergo a final intensive course of treatment with purged autologous BMT. These results are promising because in several very large multicentric studies 1,2,6,24 early relapses and general and/or hematological toxicities (especially poor hematological reconstitution precluding bone marrow harvest) have been the main limitation to autografting. In the EORTC study reported by Zittoun et al, 1 310 patients out of 623 who entered CR (49.7%) were not able to complete the scheduled protocol; in the Goelam study 24 only 59.5% of the patients achieving CR could undergo the assigned intensive treatment. Similarly in the MRC study, 2 only 381 out of the 1131 patients in CR (34%) were randomized between ABMT and no further therapy. Finally, in the study reported by Cassileth et al 6 only 261 out of the 518 patients in CR1 (50%) underwent the assigned post-remission therapy. Furthermore, in this latter study accessibility to autologous bone marrow transplantation in assigned patients was the lowest (54%) as opposed to high-dose cytarabine (91%) and allogeneic BMT (81%).
Our results were obtained through an approach which had two opposing aims: first, to improve anti-leukemic efficacy in order to increase CR rate and reduce early relapses and second, to reduce systemic and bone marrow toxicities to allow final intensification by marrow transplantation. Clearly, with the post-1989 new induction regimens the first objective was reached with a very high overall CR rate (90%). Moreover 69% of the CR were achieved following a single course of treatment. This high CR rate was an improvement over our own results before 1989 (77%) and may even compare favorably with the 65% to 75% CR rate generally reported using standard regimens in adult AML.
1,23,24,26,27 Furthermore, 81% of the patients received the two planned courses of chemotherapy. The rate of early relapse was reduced to 11%. Only 7/59 patients (11%) in CR displayed hematological toxicities precluding a marrow harvest. All other patients had satisfactory peripheral blood cell counts at the time of bone marrow harvest with a platelet count у100 × 10 9 /l. Finally, an adequate dose of stem cells in the graft was obtained through one collection in the majority of the cases (88%). The only factor related to graft feasibility in our study was the treatment given at induction and consolidation, while patients and disease characteristics, especially karyotype, had no influence. It is noteworthy that in our study, age above 50 years did not really impair the results, contrasting with other trials where the rate of CR and the OS declined with age. 18, 22, 23, 28 All these findings are consistent with two recent reports from the EBMT: a first one indicating that very high-dose aracytine given in the period preceding transplant does not improve outcome post transplant, 29 which supports our use of intermediate-dose aracytine; and a second one indicating feasibility and recent outcome improvement following ABMT in patients older than 60 years of age, indeed up to 77 years. 30 In conclusion, we show that a global approach, carefully combining and balancing the reinforcement of induction, semi-intensive consolidation and marrow grafting can bring about a consistent improvement in initial anti-leukemic efficacy while taking into account the need to maintain sufficient hematopoietic reserve to make autografting likely to be feasible. In the second part of our study we found that this approach which led to better accessibility to transplantation improved DFS and OS. This global procedure has resulted in almost 70% of the initial population and 76% of patients achieving CR1 being grafted and a DFS post graft of 60% ± 8%. This scheme should be prospectively compared with intensive chemotherapy.
